Eli Lilly and Co. and R&D and Drug discovery and Generic drugs and Health Care Businesses and Pharmaceutical

Lilly wins ban of generic Strattera pending appeal

August 31, 2010

Eli Lilly and Co., the world’s biggest maker of psychiatric drugs, won a court order banning generic versions of the attention-deficit treatment Strattera until a patent appeal is decided.

The U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday granted Lilly’s request to prevent sales until the court rules on a judge’s decision invalidating a patent on the medicine. The court, which specializes in patent law, has said it would hear the appeal quickly.

Strattera generated U.S. sales of $445.6 million last year. Sun Pharmaceuticals Industries Ltd., based in Mumbai, said earlier Tuesday that the U.S. Food and Drug Administration approved its application to sell a copy of the drug, known by its chemical name atomoxetine hydrochloride.

“Today’s ruling will prevent the launch of a generic version of Strattera while the court considers our appeal under an expedited briefing schedule,” Mark Taylor, a spokesman for Indianapolis-based Lilly, said in an e-mail.

Other companies seeking to sell copies of Strattera are Mylan Inc., Teva Pharmaceutical Industries Ltd.; Novartis AG’s Sandoz unit; Synthon BV; Iceland’s Actavis Group hf; Canada’s Apotex Inc.; and India’s Aurobindo Pharma Ltd., Glenmark Pharmaceuticals Ltd., and Cadila Healthcare Ltd.’s Zydus.
 

ADVERTISEMENT

Recent Articles by Bloomberg News

Comments powered by Disqus